Education
About Us
Working with TipRanks
Follow Us
Harrow Health (HROW)
:HROW
HROW Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.85 - $59.23
Previous CloseN/A
Volume51.77K
Average Volume (3M)601.80K
Market Cap
$1.43B
Enterprise Value$1.36B
Total Cash (Recent Filing)$52.96M
Total Debt (Recent Filing)$231.25M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Nov 17, 2025EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding37,002,136
10 Day Avg. Volume691,562
30 Day Avg. Volume601,804
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue5.99
Enterprise Value/Gross Profit8.04
Enterprise Value/Ebitda42.50
Forecast
1Y Price Target
$56.80Price Target Upside46.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Commercial StrategyHarrow has acquired exclusive U.S. commercial rights to two ophthalmology biosimilars, strengthening its commercial portfolio of ophthalmic drugs.
Financial PerformanceHarrow Health's net income exceeded expectations with $5.0M, showcasing better-than-expected financial performance.
Market ExpansionThe expansion of Harrow's pharmacy network to a full nationwide retail network is expected to stabilize and potentially increase the average selling price of VEVYE.
Bears Say
Litigation RisksThe U.S. launch date of OPUVIZ is yet to be determined due to ongoing litigation involving biosimilar manufacturers.
Market RisksRisks include lower-than-projected market uptake of products and the inability to develop and secure regulatory approval of pipeline products.
Product PerformanceVevye's $18.6 million came in below the estimate of $19.6 million and consensus of $23.1 million.
Harrow Health News
HROW FAQ
What was Harrow Health’s price range in the past 12 months?
Harrow Health lowest stock price was $20.85 and its highest was $59.23 in the past 12 months.
What is Harrow Health’s market cap?
Harrow Health’s market cap is $1.43B.
When is Harrow Health’s upcoming earnings report date?
Harrow Health’s upcoming earnings report date is Nov 17, 2025 which is in 81 days.
How were Harrow Health’s earnings last quarter?
Harrow Health released its earnings results on Aug 11, 2025. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.008 by $0.122.
Is Harrow Health overvalued?
According to Wall Street analysts Harrow Health’s price is currently Undervalued.
Does Harrow Health pay dividends?
Harrow Health does not currently pay dividends.
What is Harrow Health’s EPS estimate?
Harrow Health’s EPS estimate is 0.23.
How many shares outstanding does Harrow Health have?
Harrow Health has 37,002,136 shares outstanding.
What happened to Harrow Health’s price movement after its last earnings report?
Harrow Health reported an EPS of $0.13 in its last earnings report, beating expectations of $0.008. Following the earnings report the stock price went up 3.231%.
Which hedge fund is a major shareholder of Harrow Health?
Currently, no hedge funds are holding shares in HROW
Harrow Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.80 (46.43% Upside)
$56.80 (46.43% Upside)
Blogger Sentiment
Bullish
HROW Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 272.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 15.8%
Last 30 Days ▲ 34.6%
Last 30 Days ▲ 34.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.62%
12-Months-Change
Fundamentals
Return on Equity
-18.99%
Trailing 12-Months
Asset Growth
12.69%
Trailing 12-Months
Company Description
Harrow Health
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
HROW Company Deck
HROW Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed strong growth and strategic developments with significant revenue increases and strategic alliances. However, there were challenges with the VEVYE revenue decline and underperformance in the specialty branded portfolio.View all HROW earnings summariesHROW Stock 12 Month Forecast
Average Price Target
$56.80
▲(46.43% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
SIGA Technologies
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Ownership Overview
26.47% Insiders
9.82% Mutual Funds
24.57% Other Institutional Investors
28.38% Public Companies and Individual Investors